Contributing Member of the Healthcare Councils

Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.

GLG News by this Author

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

The implact osteoclast inhibitors on osteonecrosis

September 24, 2007

Analysis of:First osteoporosis study in patients with hip fracture finds once-yearly Aclasta(R)-Reclast(R) prevents additional fractures and improves survival | www.pipelinereview.com

The therapeutic use of a group of drugs known as bisphosphonates has been associated with a rare but destructive outcome termed osteonecrosis of the jaws (also osteonecrosis of the mandible/osteonecrosis of the maxilla.) Numerous case series and case reports have attempted to describe this phenomenon which has mostly been observed in patients taking intravenous bisphosphonates for the treatment of certain types of cancer (multiple myeloma, breast cancer and other cancers with osseous metastases) and bone disorders such as Paget’s disease of bone. The possibility of severe oral osteonecrosis can occur an the relationship with Aclasta(R)-Reclast(R) should be analyzed.

Page : 11 to 1 of 1

Subscribe to Updates

By RSS